Vol 16 - Numéro 2 Supplément 1 - octobre 2024
P. 2S1-2S297© SPLF
Cours du Groupe d'Oncologie thoracique de Langue Française - GOLF 2024
Numéro réalisé avec le soutien des laboratoires AstraZeneca, Lilly, MSD et Roche
Rev. Mal. Respir. actual October 2024; 16(2S1): i. Publication en ligne : 9 October 2024
PDF HTMLRev. Mal. Respir. actual October 2024; 16(2S1): ii. Publication en ligne : 9 October 2024
PDF HTML accès libreEditorial: The 2023 GOLF Conference
Thierry Berghmans, Alexis Cortot
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S1. Publication en ligne : 9 October 2024
PDF HTMLT. Berghmans, A. Cortot
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S2. Publication en ligne : 9 October 2024
PDF HTMLLung cancer: Epidemiology in France, Belgium and Switzerland – Main environmental and occupational risk factors
P. Andujar, B. Fervers, F. Delva, B. Clin, J.-C. Pairon
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S3. Publication en ligne : 9 October 2024
Lung oncogenesis: from molecular alteration to cancer
S. Baldacci, H. Blons, C. Mascaux, K. Leroy
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S10. Publication en ligne : 9 October 2024
Biological bases of cancer immunotherapy
C. Mascaux, L. Pabst, V. Soumelis, J. Medvedovic, C. Hoffmann
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S19. Publication en ligne : 9 October 2024
Lung cancer screening
S. Couraud, E. Grolleau, B. Milleron, V. Gounant, O. Leleu
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S27. Publication en ligne : 9 October 2024
Which anatomo-pathological work up?
M. Remmelink
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S34. Publication en ligne : 9 October 2024
Lung cancer: which molecular biology work up?
F. Escande, K. Leroy, C. Mascaux, C. Descarpentries, O. Farchi, H. Blons, M. Beau-Faller
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S42. Publication en ligne : 9 October 2024
The 9th TNM classification of thoracic oncology is born!
A. Agrafiotis, B. Grigoriu, P. Van Schil
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S49. Publication en ligne : 9 October 2024
Disease extent assessment in lung cancer
B. Grigoriu, I. Monnet, V. Gounant
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S63. Publication en ligne : 9 October 2024
Sublobar resection: a new gold standard in early NSCLC?
A. Seguin-Givelet, C. Lafouasse, D. Gossot, G. Boddaert
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S74. Publication en ligne : 9 October 2024
Stage III non-small cell bronchial cancers: what is the optimal local onset?
J. de Wolf, C. Le Péchoux, T. Berghmans
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S82. Publication en ligne : 9 October 2024
What local treatment for the management of oligometastatic NSCLC?
A. Mavrikios, P.-A. Thomas, J. Remon, A. Botticella, L. Tselikas, C. Le Péchoux, A. Levy
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S94. Publication en ligne : 9 October 2024
Surgery for Small Cell Lung Cancer
F. Le Pimpec-Barthes, L. Gibault, A.G. laffaldano, E. Fabre, C. Al Zreibi
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S109. Publication en ligne : 9 October 2024
How to optimize the operability report?
P.-E. Falcoz, T. Berghmans, M. Brandao, B. Grigoriu, A. Charloux
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S117. Publication en ligne : 9 October 2024
Management of early stages non-small cell bronchial cancers: radiotherapy in stereotactic conditions
F. Le Tinier, C. Durdux, D. Lerouge, L. Kaoutar
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S124. Publication en ligne : 9 October 2024
Radiotherapy of stage III NSCLC: new techniques, new combinations
Y. Lievens
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S130. Publication en ligne : 9 October 2024
Management of limited-stage small cell lung cancer: an update
E. Nicolas, C. Faivre-Finn, E. Giroux Leprieur, S. Ocak, P. Fournel, E. Negre, B. Roch, C. Le Pechoux
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S138. Publication en ligne : 9 October 2024
How to irradiate a patient with bronchial carcinoma under systemic treatment (targeted therapy, immunotherapy, chemotherapy agents)?
J. Doyen, V. Ferrari, M. Barret
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S147. Publication en ligne : 9 October 2024
Perioperative treatments for non-small cell lung cancer (NSCLC): Current standards and perspectives
G. Eberst, V. Westeel, M. Wislez, J. Slomka
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S153. Publication en ligne : 9 October 2024
Role of immunotherapy in unresectable stage III NSCLC
M. Pérol, J. Khalifa, H. Léna
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S161. Publication en ligne : 9 October 2024
Exensive-stage small cell lung cancer: what’s new?
S. Ocak, D. Moro-Sibilot, A. Aliouat, E. Berton, P. Fournel, A.-C. Toffart
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S169. Publication en ligne : 9 October 2024
Algorithm of NSCLC management outside oncogenic addiction
D. Moro-Sibilot, J. Mazières, G. Berardi, M. Pérol, A. Cortot
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S176. Publication en ligne : 9 October 2024
Other addictive targets ( KRAS, RET, HER2, NTRK …)
A. Cortot, P. Abdayem, D. Planchard
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S187. Publication en ligne : 9 October 2024
Therapeutic algorithm of EGFR mutation driven advanced non-small cell carcinoma
J. Cadranel, V. Fallet, S. Baldacci, M. Duruisseaux, A. Cortot
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S194. Publication en ligne : 9 October 2024
Conjugated antibodies and bispecific antibodies in lung cancer: a new hope?
M. Cani, A. Lefevre, J. Remon
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S215. Publication en ligne : 9 October 2024
Management of pleural mesothelioma in 2024
A. Scherpereel, N. Venissac, S. Humez, L. Ulmer, M. Locatelli-Sanchez, S. Brosseau, X. Dhalluin, D. Nunes, V. Gounant, S. Lantuejoul, G. Zalcman
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S226. Publication en ligne : 9 October 2024
Thymic tumors: principles of care
A. Agrafiotis, J. Arrondeau, B. Besse, N. Girard
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S239. Publication en ligne : 9 October 2024
Large cell neuroendocrine carcinoma: Update 2024
E. Gaye, A. Jannin, C. Do Cao, E. Dansin
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S250. Publication en ligne : 9 October 2024
News on bone metastases of bronchial cancers
C. Decroisette, M. Le Bon, E. Massy, A. Belliere, C. Confavreux
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S255. Publication en ligne : 9 October 2024
Oncological emergencies
A.-P. Meert, M. Ilzkovitz
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S263. Publication en ligne : 9 October 2024
Should thoracic cancer patients with respiratory failure be admitted to intensive care?
A.-C. Toffart, G. Dumas, C. Ardin, G. Berardi, F. Gonzalez
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S270. Publication en ligne : 9 October 2024
HIV and the impact on therapeutic choice
M. Brandão, E. Giroux Leprieur, A. Lavolé
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S276. Publication en ligne : 9 October 2024
Adaptation of the therapeutic plan according to age
R. Corre
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S283. Publication en ligne : 9 October 2024
Special Populations: Impact of performance status and comorbidities on the local treatment of patients with Non-Small Cell Lung Cancer
V. Gounant, R. Ezzedine, B. Duchemann, T. Pierret, S. Brosseau, Y. Castier, G. Zalcman, P. Mordant
Rev. Mal. Respir. actual October 2024; 16(2S1): 2S290. Publication en ligne : 9 October 2024